EUVIMEDEUVIMED entdecken
Crossref

Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database

Jianxing Zhou, Wei Huang, Yunzhen Xie, Haobin Shen, Maobai Liu, Xuemei Wu

Endocrine · 2024

DOI: 10.1007/s12020-024-04112-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endocrine, 2024. Verfasst von Jianxing Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Hypoglycemic Agents, Drug-Related Side Effects and Adverse Reactions, Eye Diseases. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 33 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To investigate the association between glucagon-like peptide 1 receptor agonists (GLP-1 RAs) and ophthalmic adverse drug reactions (OADRs) using data from the FDA Adverse Event Reporting System (FAERS). METHODS: This retrospective pharmacovigilance study analyzed post-marketing FAERS data from 2018 to 2023 to identify GLP-1 RA-related OADRs. This study employed the Weibull model for time-to-onset (TTO) analysis, Bayesian Information Component analysis for disproportionality comparing GLP-1 RAs with other drugs, and the Ω shrinkage method for co-medication analysis. RESULTS: FAERS reported 5003 OADRs associated with GLP-1 RAs, including retinopathy and visual impairment. Disproportionality analysis identified significant signals for semaglutide, liraglutide, and exenatide, suggesting potential associations with OADRs. Co-medication analysis indicated that OADRs primarily resulted from GLP-1 RA use. TTO analysis categorized most OADRs as early failures, emphasizing the need for early monitoring. CONCLUSION: This study emphasizes the importance of ophthalmic surveillance in patients using GLP-1 RAs, particularly semaglutide, dulaglutide, and exenatide. Enhanced monitoring and patient education are essential for timely detection and management of potential OADRs. Regulatory agencies should consider updating drug labels to include comprehensive warnings about OADRs associated with GLP-1 RA therapies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glucagon-Like Peptide-1 Receptor AgonistsHypoglycemic AgentsDrug-Related Side Effects and Adverse ReactionsEye DiseasesHumansPharmacovigilanceUnited StatesAdverse Drug Reaction Reporting SystemsUnited States Food and Drug AdministrationGlucagon-Like PeptidesRetrospective StudiesExenatideFemaleMaleMiddle AgedDatabases, FactualAgedAdultLiraglutideProduct Surveillance, PostmarketingGlucagon-Like Peptide 1Semaglutide

Stichwörter der Autor:innen

FAERS databaseGLP-1RAsObesityOphthalmic Adverse Drug ReactionsPharmacovigilanceType 2 diabetes

Substanzen

Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like PeptidesExenatideHypoglycemic AgentsLiraglutideGlucagon-Like Peptide 1Semaglutide

Autor:innen und Institutionen

  • Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China.
  • Department of Pharmacy, Zhangzhou Affiliated Hospital of Fujian Medical University, Zhangzhou, China.
  • School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu, China.
  • Department of Pharmacy, Fujian Medical University Union Hospital, Fuzhou, Fujian, China. wuxuemei@fjmu.edu.cn.

Zitieren

APA

Zhou, J., Huang, W., Xie, Y., Shen, H., Liu, M., & Wu, X. (2024). Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database. Endocrine. https://doi.org/10.1007/s12020-024-04112-8

Vancouver

Zhou J, Huang W, Xie Y, Shen H, Liu M, Wu X. Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database. Endocrine. 2024. doi:10.1007/s12020-024-04112-8

BibTeX
@article{Zhou2024,
  author = {Zhou, Jianxing and Huang, Wei and Xie, Yunzhen and Shen, Haobin and Liu, Maobai and Wu, Xuemei},
  title = {Risk of ophthalmic adverse drug reactions in patients prescribed glucagon-like peptide 1 receptor agonists: a pharmacovigilance study based on the FDA adverse event reporting system database},
  journal = {Endocrine},
  year = {2024},
  doi = {10.1007/s12020-024-04112-8}
}
Kostenlos starten →